Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METROmaJX: JX-594 and Metronomic Cyclophosphamide in Advanced Breast Cancer and Sarcoma
NCT02630368Phase 2Unknown
- Sponsor
- Institut Bergonié
- Start
- Sep 2015
- Primary completion
- May 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in soft tissue sarcoma (STS), breast cancer, sponsored by Institut Bergonié. Status: unknown.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
soft tissue sarcoma (STS)breast cancer
Beyond the preview
Go deeper on NCT02630368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630368.